By
Ottobock has announced the acquisition of Blatchford Norway A/S, the Norwegian patient care business of Blatchford Ltd., for a purchase price of approximately €110 million. The transaction gives Ottobock eight additional patient care locations, around 200 employees, and a direct presence in Norway, a market where the company says it did not previously operate its own patient care network.
The most striking figure in the announcement is the valuation. Blatchford Norway generated approximately €40 million in recent annual revenue, meaning the reported purchase price values the business at roughly 2.75 times revenue. That is a strong multiple for an O&P clinic and patient care operation, and it shows how highly strategic clinical networks are now being valued by major medtech groups.
The Valuation: €110m for €40m Revenue
On the headline numbers, the deal can be read as follows:
- Purchase price: approximately €110 million
- Recent annual revenue: approximately €40 million
- Implied revenue multiple: €110m / €40m = 2.75x revenue
- Network acquired: 8 locations
- Workforce acquired: around 200 employees
- Implied value per location: approximately €13.75 million
- Implied revenue per location: approximately €5 million
- Implied revenue per employee: approximately €200,000
These are simple calculations based on the figures disclosed by Ottobock. They do not reflect EBITDA, debt, working capital, lease obligations, tax structure or any earn-out terms that may or may not exist. But they are still useful because they show how the market may be valuing scaled, profitable, strategically located O&P patient care networks.
Ottobock also stated that the business is expected to grow revenue in the high single-digit percentage range per year over the coming years, and that, based on existing profitability and expected synergies, the acquisition should remain at Ottobock Group’s profitability level.
Why the Multiple Matters
A valuation of around 2.75x sales is not just about Norway. It sends a wider message to the O&P market: established patient care networks with strong clinical teams, market position, recurring patient relationships and predictable revenue can command meaningful strategic value.
In prosthetics and orthotics, revenue is not only generated by selling components. It is generated through clinical access, fittings, follow-up, repairs, relationships with referrers, government or insurer systems, and long-term patient care pathways. For a company like Ottobock, owning the patient care channel can strengthen both service delivery and product feedback.
Ottobock’s CEO Oliver Jakobi said the acquisition supports access to innovations, creates synergies through centralised fabrication and digital platforms, and brings the company closer to users whose feedback can inform product development.
Strategic Control of the Care Pathway
The transaction also reflects a larger trend in O&P: vertical integration. Manufacturers increasingly see value not only in producing prosthetic and orthotic components, but in owning or partnering more closely with the clinical networks that fit them.
Ottobock has already integrated local patient care leaders including Sahva in Denmark, Livit in the Netherlands and Vigo in Belgium. The Blatchford Norway acquisition continues that pattern, adding a market-leading Norwegian network to Ottobock’s wider patient care platform.
From a strategic perspective, this gives Ottobock several advantages:
- Direct access to patients and clinicians
- Stronger control over service quality and fitting pathways
- Opportunities to use centralised fabrication and digital platforms
- Better product feedback from real-world clinical use
- Greater scale in procurement, operations and training
- A stronger base for future innovation in connected O&P care
For Blatchford, the sale allows the group to transfer its Norwegian patient care business to a larger patient care platform while continuing its own focus on prosthetic and orthotic innovation. Blatchford CEO Paul Roberts said Norway had been a core part of the company’s patient care business for more than a decade.
What This Says About the Future of O&P M&A
The deal suggests that high-quality O&P clinic networks may increasingly be valued less like small local service businesses and more like strategic healthcare infrastructure.
That matters for owners of O&P clinics, regional care groups and rehabilitation service providers. A profitable, well-run clinical network with trained staff, modern systems, referral relationships and growth potential may attract strong strategic interest, particularly in markets where reimbursement is stable and demand is rising.
It also raises questions for emerging markets across IMEA. If European O&P patient care networks can command revenue multiples based on scale, growth and strategic positioning, then developing-market clinic networks may also become more investable as they professionalise.
IMEA CPO Perspective
For IMEA CPO, the Ottobock–Blatchford Norway deal is more than a European acquisition. It is a signal about where value is moving in the global O&P sector.
The value is increasingly in the full care pathway: patient access, clinical networks, data, fitting expertise, fabrication systems, digital platforms and long-term relationships. Components remain essential, but the clinic network is becoming a strategic asset.
For O&P providers across India, the Middle East and Africa, the lesson is clear. Clinics that invest in quality systems, trained staff, digital workflows, documentation, patient follow-up and scalable operations may become more valuable over time. The future of O&P is not only about selling devices. It is about building trusted care networks that can deliver consistent outcomes at scale.
